Man Zhongsong, Chen Yongqiang, Gao Lu, Xei Guowei, Li Quanfu, Lu Qian, Yan Jun
Center of Hepatobiliary Pancreatic Disease, XuZhou Central Hospital, Jiangsu, China.
Department of Clinical Laboratory, XuZhou Central Hospital, Jiangsu, China.
Front Oncol. 2021 Feb 12;10:613102. doi: 10.3389/fonc.2020.613102. eCollection 2020.
Dysregulation of RNA binding proteins (RBPs) is closely associated with tumor events. However, the function of RBPs in hepatocellular carcinoma (HCC) has not been fully elucidated. The RNA sequences and relevant clinical data of HCC were retrieved from the The Cancer Genome Atlas (TCGA) database to identify distinct RBPs. Subsequently, univariate and multivariate cox regression analysis was performed to evaluate the overall survival (OS)-associated RBPs. The expression levels of prognostic RBP genes and survival information were analyzed using a series of bioinformatics tool. A total of 365 samples with 1,542 RBPs were included in this study. One hundred and eighty-seven differently RBPs were screened, including 175 up-regulated and 12 down-regulated. The independent OS-associated RBPs of , and were used to develop a prognostic model. Survival analysis showed that low-risk patients had a significantly longer OS and disease-free survival (DFS) when compared to high-risk patients (: 2.577, : 1.793-3.704, < 0.001 and : 1.599, : 1.185-2.159, = 0.001, respectively). The International Cancer Genome Consortium (ICGC) database was used to externally validate the model, and the OS of low-risk patients were found to be longer than that of high-risk patients ( < 0.001). The Nomograms of OS and DFS were plotted to help in clinical decision making. These results showed that the model was effective and may help in prognostic stratification of HCC patients. The prognostic prediction model based on RBPs provides new insights for HCC diagnosis and personalized treatment.
RNA结合蛋白(RBPs)的失调与肿瘤事件密切相关。然而,RBPs在肝细胞癌(HCC)中的功能尚未完全阐明。从癌症基因组图谱(TCGA)数据库中检索HCC的RNA序列和相关临床数据,以识别不同的RBPs。随后,进行单因素和多因素cox回归分析,以评估与总生存期(OS)相关的RBPs。使用一系列生物信息学工具分析预后RBP基因的表达水平和生存信息。本研究共纳入365个样本,包含1542个RBPs。筛选出187个差异RBPs,其中175个上调,12个下调。使用、和的独立OS相关RBPs建立预后模型。生存分析表明,与高危患者相比,低危患者的OS和无病生存期(DFS)显著更长(分别为:2.577,:1.793 - 3.704,<0.001;:1.599,:1.185 - 2.159,=0.001)。使用国际癌症基因组联盟(ICGC)数据库对该模型进行外部验证,发现低危患者的OS长于高危患者(<0.001)。绘制OS和DFS的列线图以帮助临床决策。这些结果表明该模型有效,可能有助于HCC患者的预后分层。基于RBPs的预后预测模型为HCC诊断和个性化治疗提供了新的见解。